FDA clears combined use of Solventum's Restrata matrix and V.A.C. therapy

Overview

Updated Yesterday

The FDA cleared Solventum to use its Restrata synthetic tissue matrix under its V.A.C. negative pressure wound therapy — the first clearance combining the two technologies. Clinicians can now place a fully synthetic, resorbable scaffold beneath a vacuum dressing that stays on for up to seven days.

The decision caps an 11-month integration. Solventum bought Restrata's maker, Acera Surgical, in December 2025 for $725 million. The combined therapy targets complex surgical and traumatic wounds in acute care, where collagen-based dressings often degrade before the vacuum dressing comes off.

Why it matters

If the combination gains traction, wound care teams get a synthetic matrix that survives a full seven-day vacuum cycle — fewer dressing changes, more predictable healing.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$725M

Acera Surgical acquisition price

Solventum paid $725 million in cash plus up to $125 million in contingent milestone payments.

$90M

Acera's expected 2025 sales

Acera was projected to generate about $90 million in sales in 2025 before the acquisition closed.

7 days

V.A.C. dressing wear time

The V.A.C. Peel and Place Dressing can stay on for up to seven days per application.

100%

Restrata's synthetic composition

Restrata is a fully synthetic, resorbable matrix that resists enzymatic degradation.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

People Involved

Bryan Hanson

Chief Executive Officer, Solventum

Active

Organizations Involved

Solventum

Medical technology company

NYSE-listed (SOLV), leader in advanced wound healing

Solventum develops advanced wound care technologies, including negative pressure wound therapy and synthetic tissue matrices.

Acera Surgical

Bioscience company

Acquired by Solventum in December 2025

Developed Restrata, a synthetic electrospun fiber matrix for soft tissue repair.

U.S. Food and Drug Administration

Federal regulatory agency

Granted 510(k) clearance for combined Restrata + V.A.C. use

The FDA regulates medical devices in the United States through its 510(k) clearance pathway.

Timeline

2013 October 2026

4 events Latest: Yesterday

Tap a bar to jump to that date

October 2026
FDA clears combined Restrata + V.A.C. use
Latest Regulatory

FDA grants 510(k) clearance for combined use of Restrata matrix and V.A.C. therapy, a first-of-its-kind pairing.
Yesterday
December 2025
Acquisition completed
Acquisition

Solventum completes its acquisition of Acera Surgical, adding Restrata to its wound care portfolio.
December 2025
November 2025
Solventum announces Acera acquisition
Acquisition

Solventum agrees to buy Acera Surgical for $725 million cash plus up to $125 million in milestone payments.
November 20th, 2025
2013
Acera Surgical founded
Founding

Acera Surgical founded to develop synthetic tissue matrices for regenerative wound care.
2013

Scenarios

Combined therapy becomes standard for complex acute wounds

Likely Resolves by End of 2027

Discussed by: Solventum's press release and investor communications

Solventum's specialized wound care sales force pushes the combined therapy into acute care settings. The seven-day wear time and resistance to enzymatic degradation reduce dressing changes and streamline workflows, driving adoption across hospitals and wound care centers.

Reimbursement and cost barriers slow adoption

Possible Resolves by End of 2027

Discussed by: Healthcare analysts covering medical device reimbursement

Hospitals face budget pressure and the combined therapy carries a premium price. Without clear reimbursement pathways, adoption stays limited to specialized wound care centers and major trauma hospitals, capping the therapy's market reach.

Rivals develop competing synthetic matrix + NPWT combinations

Possible Resolves by Q2 2028

Discussed by: Industry analysts tracking the wound care market

Competitors develop their own synthetic matrices cleared for use with negative pressure wound therapy, eroding Solventum's first-mover advantage. The FDA's 510(k) pathway allows substantially equivalent devices to reach market more quickly.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

1990s

V.A.C. Therapy's rise as the first NPWT system (1990s)

V.A.C. Therapy became the first commercially available negative pressure wound therapy system. It has since helped treat 11 million wounds worldwide and remains the most studied NPWT solution.

Then

Negative pressure wound therapy became a standard tool for complex wound management in acute care.

Now

V.A.C. Therapy's dominance established NPWT as a core wound care modality, with 11 million wounds treated to date.

Why this matters now

Shows how a first-of-its-kind wound care technology can become a standard of care — the pattern Solventum hopes to repeat with the combined Restrata + V.A.C. therapy.

Ongoing

Collagen dressings' limits under negative pressure (ongoing)

Collagen-based dressings have been a standard for soft tissue repair but degrade prematurely under negative pressure wound therapy. Restrata's fully synthetic profile resists enzymatic degradation, addressing this known limitation.

Then

Clinicians had to change dressings more frequently when using collagen matrices with NPWT.

Now

The FDA clearance positions synthetic matrices as a viable alternative for combined use with NPWT, potentially shifting clinical practice.

Why this matters now

Explains why the combined clearance matters — it directly addresses a documented weakness of collagen-based dressings in NPWT applications.